An open randomised trial to evaluate the activity and tolerability of combinations of reverse transcriptase and protease inhibitors, including induction therapy, in individuals with Human Immunodeficiency Virus-1 (HIV-1) infection and CD4 cell counts greater than 25 x 10 to the power of 6 per litre

Medical Research Council (MRC) (UK)0 个研究点目标入组 100 人开始时间: 2000年10月3日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Age 18 years or more with documented HIV-1 infection and requiring anti-retroviral therapy
•2. CD4 count greater than 25 x 10 to the power of 6 per litre
•3. Any stage of HIV disease including recent infection (except acute symptomatic primary infection)
•4. Likely to survive at least 2 years and take the allocated therapy for at least 6 months
•5. Able to give informed consent

•1. Previous anti-retroviral treatment or immunotherapies
•2. Peripheral nephropathy or a history of pancreatitis
•3. Women who are pregnant, breastfeeding or not taking adequate contraception
•4. Heterosexual men not willing to use barrier contraception
•5. Receiving combination chemotherapy for cancer
•6. Receiving parenteral therapy for an opportunistic infection
•7. Unlikely to comply with the protocol
•8. At screening with creatinine above upper limit of normal (ULN), ALT or AST above 2.5 times ULN, amylase above 1.5 times ULN (except if pancreatic amylase less than 1.5 times ULN), haemoglobin less than 10.5g/dl, neutrophils less than 1.0 or platelets less than 100

发起方

Medical Research Council (MRC) (UK)